Similar articles

• Factors impacting the combination of topical corticosteroid therapies for psoriasis: perspectives from the International Psoriasis Council.

  van de Kerkhof PC, Kragballe K, Segaert S, Lebwohl M; International Psoriasis Council. van de Kerkhof PC, et al. J Eur Acad Dermatol Venereol. 2011 Oct;25(10):1130-9. doi: 10.1111/j.1468-3083.2011.04113.x. Epub 2011 May 13. J Eur Acad Dermatol Venereol. 2011. PMID: 21564329 Review.
• Topical corticosteroids in psoriasis: strategies for improving safety.

  Horn EJ, Domm S, Katz HI, Lebwohl M, Mrowietz U, Kragballe K; International Psoriasis Council. Horn EJ, et al. J Eur Acad Dermatol Venereol. 2010 Feb;24(2):119-24. doi: 10.1111/j.1468-3083.2009.03358.x. Epub 2009 Jul 3. J Eur Acad Dermatol Venereol. 2010. PMID: 20175860 Review.
• Placebo response?

  Feldman SR. Feldman SR. Psychosom Med. 2010 Jun;72(5):505; author reply 505-6. doi: 10.1097/PSY.0b013e3181e2d141. Epub 2010 May 24. Psychosom Med. 2010. PMID: 20498291 No abstract available.
• Topical antipsoriatics.

  Smith KC, Lebwohl M. Smith KC, et al. Skin Therapy Lett. 2000;5(2):1-2. Skin Therapy Lett. 2000. PMID: 10751842 Review.
• Pharmacoeconomic model of topical treatment options of mild to moderate psoriasis vulgaris in Germany.

  Augustin M, Radtke M, van Engen A, Ruedig C, Lapp C, Moehling U. Augustin M, et al. J Dtsch Dermatol Ges. 2009 Apr;7(4):329-38. doi: 10.1111/j.1610-0387.2008.06919.x. Epub 2009 Feb 20. J Dtsch Dermatol Ges. 2009. PMID: 19243481 English, German.